Regulation of the DNA damage response by ubiquitin conjugation

Frontiers in Genetics

Volumn 6, Issue MAR, 2015, Pages

  Brinkmann, Kerstin ^a,c   Schell, Michael ^a,b   Hoppe, Thorsten ^a,b   Kashkar, Hamid ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Apoptosis; Bcl 2; DNA damage; Genotoxic anti cancer therapy; P53; Ubiquitylation

Indexed keywords

EID: 84923588668     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2015.00098     Document Type: Review

References (207)

1. Abou Zeinab, R., Wu, H., Sergi, C., and Leng, R. P. (2013). Residues 240-250 in the C-terminus of the Pirh2 protein complement the function of the RING domain in self-ubiquitination of the Pirh2 protein. PLoS ONE 8:e82803. doi: 10.1371/journal.pone.0082803.
2. Acs, K., Luijsterburg, M. S., Ackermann, L., Salomons, F. A., Hoppe, T., and Dantuma, N. P. (2011). The AAA-ATPase VCP/p97 promotes 53BP1 recruitment by removing L3MBTL1 from DNA double-strand breaks. Nat. Struct. Mol. Biol. 18, 1345-1350. doi: 10.1038/nsmb.2188.
3. Adams, J. M., and Cory, S. (1998). The Bcl-2 protein family: arbiters of cell survival. Science 281, 1322-1326. doi: 10.1126/science.281.5381.1322.
4. Adams, J. M., and Cory, S. (2007). The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26, 1324-1337. doi: 10.1038/sj.onc.1210220.
5. Akiyama, T., Bouillet, P., Miyazaki, T., Kadono, Y., Chikuda, H., Chung, U. I., et al. (2003). Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. EMBO J. 22, 6653-6664. doi: 10.1093/emboj/cdg635.
6. Al-Hakim, A., Escribano-Diaz, C., Landry, M. C., O'Donnell, L., Panier, S., Szilard, R. K., et al. (2010). The ubiquitous role of ubiquitin in the DNA damage response. DNA Repair (Amst). 9, 1229-1240. doi: 10.1016/j.dnarep.2010.09.011.
7. Allende-Vega, N., Sparks, A., Lane, D. P., and Saville, M. K. (2010). MdmX is a substrate for the deubiquitinating enzyme USP2a. Oncogene 29, 432-441. doi: 10.1038/onc.2009.330.
8. Ambrosini, G., Seelman, S. L., and Schwartz, G. K. (2009). Differentiation-related gene-1 decreases Bim stability by proteasome-mediated degradation. Cancer Res. 69, 6115-6121. doi: 10.1158/0008-5472.CAN-08-3024.
9. Aylon, Y., and Oren, M. (2007). Living with p53, dying of p53. Cell 130, 597-600. doi: 10.1016/j.cell.2007.08.005.
10. Azad, N., Vallyathan, V., Wang, L., Tantishaiyakul, V., Stehlik, C., Leonard, S. S., et al. (2006). S-nitrosylation of Bcl-2 inhibits its ubiquitin-proteasomal degradation. A novel antiapoptotic mechanism that suppresses apoptosis. J. Biol. Chem. 281, 34124-34134. doi: 10.1074/jbc. M602551200.
11. Azakir, B. A., Desrochers, G., and Angers, A. (2010). The ubiquitin ligase Itch mediates the antiapoptotic activity of epidermal growth factor by promoting the ubiquitylation and degradation of the truncated C-terminal portion of Bid. FEBS J. 277, 1319-1330. doi: 10.1111/j.1742-4658.2010.07562.x.
12. Badciong, J. C., and Haas, A. L. (2002). MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination. J. Biol. Chem. 277, 49668-49675. doi: 10.1074/jbc. M208593200.
13. Balint, E., Bates, S., and Vousden, K. H. (1999). Mdm2 binds p73 alpha without targeting degradation. Oncogene 18, 3923-3929. doi: 10.1038/sj.onc.1202781.
14. Banin, S., Moyal, L., Shieh, S., Taya, Y., Anderson, C. W., Chessa, L., et al. (1998). Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281, 1674-1677. doi: 10.1126/science.281.5383.1674.
15. Baou, M., Kohlhaas, S. L., Butterworth, M., Vogler, M., Dinsdale, D., Walewska, R., et al. (2010). Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica 95, 1510-1518. doi: 10.3324/haematol.2010.022368.
16. Bartel, F., Taubert, H., and Harris, L. C. (2002). Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2, 9-15. doi: 10.1016/S1535-6108(02)00091-0.
17. Basu, A., and Haldar, S. (2002). Signal-induced site specific phosphorylation targets Bcl2 to the proteasome pathway. Int. J. Oncol. 21, 597-601. doi: 10.3892/ijo.21.3.597.
18. Biswas, M., Voltz, K., Smith, J. C., and Langowski, J. (2011). Role of histone tails in structural stability of the nucleosome. PLoS Comput. Biol. 7:e1002279. doi: 10.1371/journal.pcbi.1002279.
19. Bohgaki, M., Hakem, A., Halaby, M. J., Bohgaki, T., Li, Q., Bissey, P. A., et al. (2013). The E3 ligase PIRH2 polyubiquitylates CHK2 and regulates its turnover. Cell Death Differ. 20, 812-822. doi: 10.1038/cdd.2013.7.
20. Breitschopf, K., Bengal, E., Ziv, T., Admon, A., and Ciechanover, A. (1998). A novel site for ubiquitination: the N-terminal residue, and not internal lysines of MyoD, is essential for conjugation and degradation of the protein. EMBO J. 17, 5964-5973. doi: 10.1093/emboj/17.20.5964.
21. Breitschopf, K., Haendeler, J., Malchow, P., Zeiher, A. M., and Dimmeler, S. (2000a). Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. Mol. Cell. Biol. 20, 1886-1896. doi: 10.1128/MCB.20.5.1886-1896.2000.
22. Breitschopf, K., Zeiher, A. M., and Dimmeler, S. (2000b). Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J. Biol. Chem. 275, 21648-21652. doi: 10.1074/jbc. M001083200.
23. Brinkmann, K., and Kashkar, H. (2014). Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies? Cell Death Dis. 5:e1098. doi: 10.1038/cddis.2014.61.
24. Brinkmann, K., Zigrino, P., Witt, A., Schell, M., Ackermann, L., Broxtermann, P., et al. (2013). Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by stabilizing NOXA. Cell Rep. 3, 881-891. doi: 10.1016/j.celrep.2013.02.014.
25. Bueso-Ramos, C. E., Manshouri, T., Haidar, M. A., Yang, Y., McCown, P., Ordonez, N., et al. (1996). Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res. Treat. 37, 179-188. doi: 10.1007/BF01806499.
26. Bueso-Ramos, C. E., Yang, Y., deLeon, E., McCown, P., Stass, S. A., and Albitar, M. (1993). The human MDM-2 oncogene is overexpressed in leukemias. Blood 82, 2617-2623.
27. Bunting, S. F., and Nussenzweig, A. (2013). End-joining, translocations and cancer. Nat. Rev. Cancer 13, 443-454. doi: 10.1038/nrc3537.
28. Chang, Y. C., Lee, Y. S., Tejima, T., Tanaka, K., Omura, S., Heintz, N. H., et al. (1998). mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ. 9, 79-84.
29. Chanvorachote, P., Nimmannit, U., Stehlik, C., Wang, L., Jiang, B. H., Ongpipatanakul, B., et al. (2006). Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination. Cancer Res. 66, 6353-6360. doi: 10.1158/0008-5472.CAN-05-4533.
30. Chapman, J. R., Taylor, M. R., and Boulton, S. J. (2012). Playing the end game: DNA double-strand break repair pathway choice. Mol. Cell 47, 497-510. doi: 10.1016/j.molcel.2012.07.029.
31. Chen, D., Kon, N., Li, M., Zhang, W., Qin, J., and Gu, W. (2005b). ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121, 1071-1083. doi: 10.1016/j.cell.2005.03.037.
32. Chen, S., Davies, A. A., Sagan, D., and Ulrich, H. D. (2005a). The RING finger ATPase Rad5p of Saccharomyces cerevisiae contributes to DNA double-strand break repair in a ubiquitin-independent manner. Nucleic Acids Res. 33, 5878-5886. doi: 10.1093/nar/gki902.
33. Cheng, Q., and Chen, J. (2010). Mechanism of p53 stabilization by ATM after DNA damage. Cell Cycle 9, 472-478. doi: 10.4161/cc.9.3.10556.
34. Cheung, H. W., Ching, Y. P., Nicholls, J. M., Ling, M. T., Wong, Y. C., Hui, N., et al. (2005). Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation. Mol. Carcinog. 43, 237-245. doi: 10.1002/mc.20106.
35. Ciechanover, A., Finley, D., and Varshavsky, A. (1984). Ubiquitin dependence of selective protein degradation demonstrated in the mammalian cell cycle mutant ts85. Cell 37, 57-66. doi: 10.1016/0092-8674(84)90300-3.
36. Ciechanover, A., Finley, D., and Varshavsky, A. (1985). Mammalian cell cycle mutant defective in intracellular protein degradation and ubiquitin-protein conjugation. Prog. Clin. Biol. Res. 180, 17-31.
37. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., et al. (1993). Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849-852. doi: 10.1038/362849a0.
38. Clejan, I., Boerckel, J., and Ahmed, S. (2006). Developmental modulation of nonhomologous end joining in Caenorhabditis elegans. Genetics 173, 1301-1317. doi: 10.1534/genetics.106.058628.
39. Cory, S., and Adams, J. M. (2002). The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2, 647-656. doi: 10.1038/nrc883.
40. Craxton, A., Butterworth, M., Harper, N., Fairall, L., Schwabe, J., Ciechanover, A., et al. (2012). NOXA, a sensor of proteasome integrity, is degraded by 26S proteasomes by an ubiquitin-independent pathway that is blocked by MCL-1. Cell Death Differ. 19, 1424-1434. doi: 10.1038/cdd.2012.16.
41. Cummins, J. M., and Vogelstein, B. (2004). HAUSP is required for p53 destabilization. Cell Cycle 3, 689-692. doi: 10.4161/cc.3.6.924.
42. Dahm-Daphi, J., Hubbe, P., Horvath, F., El-Awady, R. A., Bouffard, K. E., Powell, S. N., et al. (2005). Nonhomologous end-joining of site-specific but not of radiation-induced DNA double-strand breaks is reduced in the presence of wild-type p53. Oncogene 24, 1663-1672. doi: 10.1038/sj.onc.1208396.
43. Daigaku, Y., Davies, A. A., and Ulrich, H. D. (2010). Ubiquitin-dependent DNA damage bypass is separable from genome replication. Nature 465, 951-955. doi: 10.1038/nature09097.
44. Dantuma, N. P., and Hoppe, T. (2012). Growing sphere of influence: Cdc48/p97 orchestrates ubiquitin-dependent extraction from chromatin. Trends Cell Biol. 22, 483-491. doi: 10.1016/j.tcb.2012.06.003.
45. de Graaf, P., Little, N. A., Ramos, Y. F., Meulmeester, E., Letteboer, S. J., and Jochemsen, A. G. (2003). Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. J. Biol. Chem. 278, 38315-38324. doi: 10.1074/jbc. M213034200.
46. Dehan, E., Bassermann, F., Guardavaccaro, D., Vasiliver-Shamis, G., Cohen, M., Lowes, K. N., et al. (2009). BetaTrCP-and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol. Cell 33, 109-116. doi: 10.1016/j.molcel.2008.12.020.
47. Dengler, M. A., Weilbacher, A., Gutekunst, M., Staiger, A. M., Vohringer, M. C., Horn, H., et al. (2014). Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma. Cell Death Dis. 5, e1013. doi: 10.1038/cddis.2013.552.
48. Di Conza, G., Mancini, F., Buttarelli, M., Pontecorvi, A., Trimarchi, F., and Moretti, F. (2012). MDM4 enhances p53 stability by promoting an active conformation of the protein upon DNA damage. Cell Cycle 11, 749-760. doi: 10.4161/cc.11.4.19208.
49. Dimmeler, S., Breitschopf, K., Haendeler, J., and Zeiher, A. M. (1999). Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway. J. Exp. Med. 189, 1815-1822. doi: 10.1084/jem.189.11.1815.
50. Ding, Q., He, X., Hsu, J. M., Xia, W., Chen, C. T., Li, L. Y., et al. (2007). Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol. Cell. Biol. 27, 4006-4017. doi: 10.1128/MCB.00620-06.
51. Doil, C., Mailand, N., Bekker-Jensen, S., Menard, P., Larsen, D. H., Pepperkok, R., et al. (2009). RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell 136, 435-446. doi: 10.1016/j.cell.2008.12.041.
52. Dornan, D., Bheddah, S., Newton, K., Ince, W., Frantz, G. D., Dowd, P., et al. (2004b). COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res. 64, 7226-7230. doi: 10.1158/0008-5472.CAN-04-2601.
53. Dornan, D., Shimizu, H., Mah, A., Dudhela, T., Eby, M., O'Rourke, K., et al. (2006). ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage. Science 313, 1122-1126. doi: 10.1126/science.1127335.
54. Dornan, D., Wertz, I., Shimizu, H., Arnott, D., Frantz, G. D., Dowd, P., et al. (2004a). The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429, 86-92. doi: 10.1038/nature02514.
55. Duan, S., Yao, Z., Hou, D., Wu, Z., Zhu, W. G., and Wu, M. (2007). Phosphorylation of Pirh2 by calmodulin-dependent kinase II impairs its ability to ubiquitinate p53. EMBO J. 26, 3062-3074. doi: 10.1038/sj.emboj.7601749.
56. Duan, W., Gao, L., Druhan, L. J., Zhu, W. G., Morrison, C., Otterson, G. A., et al. (2004). Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. J. Natl. Cancer Inst. 96, 1718-1721. doi: 10.1093/jnci/djh292.
57. Dworakowska, D., Jassem, E., Jassem, J., Peters, B., Dziadziuszko, R., Zylicz, M., et al. (2004). MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC). Lung Cancer 43, 285-295. doi: 10.1016/j.lungcan.2003.09.010.
58. Erson, A. E., and Petty, E. M. (2004). CHFR-associated early G2/M checkpoint defects in breast cancer cells. Mol. Carcinog. 39, 26-33. doi: 10.1002/mc.10161.
59. Feng, L., and Chen, J. (2012). The E3 ligase RNF8 regulates KU80 removal and NHEJ repair. Nat. Struct. Mol. Biol. 19, 201-206. doi: 10.1038/nsmb.2211.
60. Gomez-Bougie, P., Menoret, E., Juin, P., Dousset, C., Pellat-Deceunynck, C., and Amiot, M. (2011). Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1/USP9X interaction. Biochem. Biophys. Res. Commun. 413, 460-464. doi: 10.1016/j.bbrc.2011.08.118.
61. Haglund, K., and Dikic, I. (2005). Ubiquitylation and cell signaling. EMBO J. 24, 3353-3359. doi: 10.1038/sj.emboj.7600808.
62. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674. doi: 10.1016/j.cell.2011.02.013.
63. Harley, M. E., Allan, L. A., Sanderson, H. S., and Clarke, P. R. (2010). Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J. 29, 2407-2420. doi: 10.1038/emboj.2010.112.
64. Hershko, A., and Ciechanover, A. (1998). The ubiquitin system. Annu. Rev. Biochem. 67, 425-479. doi: 10.1146/annurev.biochem.67.1.425.
65. Hershko, A., Heller, H., Elias, S., and Ciechanover, A. (1983). Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J. Biol. Chem. 258, 8206-8214.
66. Hock, A. K., Vigneron, A. M., Carter, S., Ludwig, R. L., and Vousden, K. H. (2011). Regulation of p53 stability and function by the deubiquitinating enzyme USP42. EMBO J. 30, 4921-4930. doi: 10.1038/emboj.2011.419.
67. Hoege, C., Pfander, B., Moldovan, G. L., Pyrowolakis, G., and Jentsch, S. (2002). RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 419, 135-141. doi: 10.1038/nature00991.
68. Hollstein, M., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sorlie, T., et al. (1994). Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22, 3551-3555.
69. Hoppe, T. (2005). Multiubiquitylation by E4 enzymes: 'one size' doesn't fit all. Trends Biochem. Sci. 30, 183-187. doi: 10.1016/j.tibs.2005.02.004.
70. Hosoda, M., Ozaki, T., Miyazaki, K., Hayashi, S., Furuya, K., Watanabe, K., et al. (2005). UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination. Oncogene 24, 7156-7169. doi: 10.1038/sj.onc.1208872.
71. Hu, L., Liu, M., Chen, L., Chan, T. H., Wang, J., Huo, K. K., et al. (2012). SCYL1 binding protein 1 promotes the ubiquitin-dependent degradation of Pirh2 and has tumor-suppressive function in the development of hepatocellular carcinoma. Carcinogenesis 33, 1581-1588. doi: 10.1093/carcin/bgs162.
72. Hur, J., Chesnes, J., Coser, K. R., Lee, R. S., Geck, P., Isselbacher, K. J., et al. (2004). The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis. Proc. Natl. Acad. Sci. U.S.A. 101, 2351-2356. doi: 10.1073/pnas.0307337101.
73. Inoue, S., Hao, Z., Elia, A. J., Cescon, D., Zhou, L., Silvester, J., et al. (2013). Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15. Genes Dev. 27, 1101-1114. doi: 10.1101/gad.214577.113.
74. Inuzuka, H., Shaik, S., Onoyama, I., Gao, D., Tseng, A., Maser, R. S., et al. (2011). SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 471, 104-109. doi: 10.1038/nature09732.
75. Irminger-Finger, I., and Jefford, C. E. (2006). Is there more to BARD1 than BRCA1? Nat. Rev. Cancer 6, 382-391. doi: 10.1038/nrc1878.
76. Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G., Masucci, M., et al. (2004). Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10, 1321-1328. doi: 10.1038/nm1146.
77. Jackson, S. P., and Durocher, D. (2013). Regulation of DNA damage responses by ubiquitin and SUMO. Mol. Cell 49, 795-807. doi: 10.1016/j.molcel.2013.01.017.
78. Jia, L., Gorman, G. S., Coward, L. U., Noker, P. E., McCormick, D., Horn, T. L., et al. (2011). Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination. Cancer Chemother. Pharmacol. 68, 513-524. doi: 10.1007/s00280-010-1518-3.
79. Jiang, N., Shen, Y., Fei, X., Sheng, K., Sun, P., Qiu, Y., et al. (2013). Valosin-containing protein regulates the proteasome-mediated degradation of DNA-PKcs in glioma cells. Cell Death Dis. 4, e647. doi: 10.1038/cddis.2013.171.
80. Jung, Y. S., Qian, Y., and Chen, X. (2011). The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation. J. Biol. Chem. 286, 35388-35395. doi: 10.1074/jbc. M111.261537.
81. Kadakia, M., Slader, C., and Berberich, S. J. (2001). Regulation of p63 function by Mdm2 and MdmX. DNA Cell Biol. 20, 321-330. doi: 10.1089/10445490152122433.
82. Kawai, H., Wiederschain, D., Kitao, H., Stuart, J., Tsai, K. K., and Yuan, Z. M. (2003). DNA damage-induced MDMX degradation is mediated by MDM2. J. Biol. Chem. 278, 45946-45953. doi: 10.1074/jbc. M308295200.
83. Khoronenkova, S. V., and Dianov, G. L. (2013). USP7S-dependent inactivation of Mule regulates DNA damage signalling and repair. Nucleic Acids Res. 41, 1750-1756. doi: 10.1093/nar/gks1359.
84. Khosravi, R., Maya, R., Gottlieb, T., Oren, M., Shiloh, Y., and Shkedy, D. (1999). Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc. Natl. Acad. Sci. U.S.A. 96, 14973-14977. doi: 10.1073/pnas.96.26.14973.
85. Kim, S. T., Lim, D. S., Canman, C. E., and Kastan, M. B. (1999). Substrate specificities and identification of putative substrates of ATM kinase family members. J. Biol. Chem. 274, 37538-37543. doi: 10.1074/jbc.274.53.37538.
86. Koegl, M., Hoppe, T., Schlenker, S., Ulrich, H. D., Mayer, T. U., and Jentsch, S. (1999). A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 96, 635-644. doi: 10.1016/S0092-8674(00)80574-7.
87. Komander, D., and Rape, M. (2012). The ubiquitin code. Annu. Rev. Biochem. 81, 203-229. doi: 10.1146/annurev-biochem-060310-170328.
88. Krajewski, M., Ozdowy, P., D'Silva, L., Rothweiler, U., and Holak, T. A. (2005). NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat. Med. 11, 1135-1136. doi: 10.1038/nm1105-1135.
89. Kucharczak, J. F., Simmons, M. J., Duckett, C. S., and Gelinas, C. (2005). Constitutive proteasome-mediated turnover of Bfl-1/A1 and its processing in response to TNF receptor activation in FL5.12 pro-B cells convert it into a prodeath factor. Cell Death Differ. 12, 1225-1239. doi: 10.1038/sj.cdd.4401684.
90. Lai, Z., Ferry, K. V., Diamond, M. A., Wee, K. E., Kim, Y. B., Ma, J., et al. (2001). Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization. J. Biol. Chem. 276, 31357-31367. doi: 10.1074/jbc. M011517200.
91. Laptenko, O., and Prives, C. (2006). Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ. 13, 951-961. doi: 10.1038/sj.cdd.4401916.
92. Lee, Y. H., Andersen, J. B., Song, H. T., Judge, A. D., Seo, D., Ishikawa, T., et al. (2010). Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma. Cancer Res. 70, 8264-8269. doi: 10.1158/0008-5472.CAN-10-0749.
93. Lemmens, B. B., and Tijsterman, M. (2010). DNA double-strand break repair in Caenorhabditis elegans. Chromosoma 120, 1-21. doi: 10.1007/s00412-010-0296-3.
94. Leng, R. P., Lin, Y., Ma, W., Wu, H., Lemmers, B., Chung, S., et al. (2003). Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112, 779-791. doi: 10.1016/S0092-8674(03)00193-4.
95. Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., and Korsmeyer, S. J. (2002). Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2, 183-192. doi: 10.1016/S1535-6108(02)00127-7.
96. Levine, J. S., Koh, J. S., Triaca, V., and Lieberthal, W. (1997). Lysophosphatidic acid: a novel growth and survival factor for renal proximal tubular cells. Am. J. Physiol. 273, F575-F585.
97. Levinger, L., and Varshavsky, A. (1980). High-resolution fractionation of nucleosomes: minor particles, "whiskers" and separation of mononucleosomes containing and lacking A24 semihistone. Proc. Natl. Acad. Sci. U.S.A. 77, 3244-3248. doi: 10.1073/pnas.77.6.3244.
98. Ley, R., Balmanno, K., Hadfield, K., Weston, C., and Cook, S. J. (2003). Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J. Biol. Chem. 278, 18811-18816. doi: 10.1074/jbc. M301010200.
99. Li, B., and Dou, Q. P. (2000). Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc. Natl. Acad. Sci. U.S.A. 97, 3850-3855. doi: 10.1073/pnas.070047997.
100. Li, H., Tan, M., Jia, L., Wei, D., Zhao, Y., Chen, G., et al. (2014). Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis. J. Clin. Invest. 124, 835-846. doi: 10.1172/JCI70297.
101. Li, L., Tao, Q., Jin, H., van Hasselt, A., Poon, F. F., Wang, X., et al. (2010). The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin. Cancer Res. 16, 2949-2958. doi: 10.1158/1078-0432.CCR-09-3178.
102. Li, M., Brooks, C. L., Kon, N., and Gu, W. (2004). A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol. Cell 13, 879-886. doi: 10.1016/S1097-2765(04)00157-1.
103. Li, M., Chen, D., Shiloh, A., Luo, J., Nikolaev, A. Y., Qin, J., et al. (2002). Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416, 648-653. doi: 10.1038/nature737.
104. Li, W., Nagaraja, S., Delcuve, G. P., Hendzel, M. J., and Davie, J. R. (1993). Effects of histone acetylation, ubiquitination and variants on nucleosome stability. Biochem. J. 296(Pt 3), 737-744.
105. Li, Y. F., Wang, D. D., Zhao, B. W., Wang, W., Huang, C. Y., Chen, Y. M., et al. (2012). High level of COP1 expression is associated with poor prognosis in primary gastric cancer. Int. J. Biol. Sci. 8, 1168-1177. doi: 10.7150/ijbs.4778.
106. Linke, K., Mace, P. D., Smith, C. A., Vaux, D. L., Silke, J., and Day, C. L. (2008). Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ. 15, 841-848. doi: 10.1038/sj.cdd.4402309.
107. Liu, C., Wu, J., Paudyal, S. C., You, Z., and Yu, X. (2013). CHFR is important for the first wave of ubiquitination at DNA damage sites. Nucleic Acids Res. 41, 1698-1710. doi: 10.1093/nar/gks1278.
108. Liu, J., Chung, H. J., Vogt, M., Jin, Y., Malide, D., He, L., et al. (2011). JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress. EMBO J. 30, 846-858. doi: 10.1038/emboj.2011.11.
109. Logan, I. R., Gaughan, L., McCracken, S. R., Sapountzi, V., Leung, H. Y., and Robson, C. N. (2006). Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer. Mol. Cell. Biol. 26, 6502-6510. doi: 10.1128/MCB.00147-06.
110. Logan, I. R., Sapountzi, V., Gaughan, L., Neal, D. E., and Robson, C. N. (2004). Control of human PIRH2 protein stability: involvement of TIP60 and the proteosome. J. Biol. Chem. 279, 11696-11704. doi: 10.1074/jbc. M312712200.
111. Lok, G. T., Sy, S. M., Dong, S. S., Ching, Y. P., Tsao, S. W., Thomson, T. M., et al. (2012). Differential regulation of RNF8-mediated Lys48-and Lys63-based poly-ubiquitylation. Nucleic Acids Res. 40, 196-205. doi: 10.1093/nar/gkr655.
112. Lord, C. J., and Ashworth, A. (2012). The DNA damage response and cancer therapy. Nature 481, 287-294. doi: 10.1038/nature10760.
113. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. (1993). p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849. doi: 10.1038/362847a0.
114. Lu, X., Ma, O., Nguyen, T. A., Jones, S. N., Oren, M., and Donehower, L. A. (2007). The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 12, 342-354. doi: 10.1016/j.ccr.2007.08.033.
115. Luo, X., Budihardjo, I., Zou, H., Slaughter, C., and Wang, X. (1998). Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94, 481-490. doi: 10.1016/S0092-8674(00)81589-5.
116. Magiera, M. M., Mora, S., Mojsa, B., Robbins, I., Lassot, I., and Desagher, S. (2013). Trim17-mediated ubiquitination and degradation of Mcl-1 initiate apoptosis in neurons. Cell Death Differ. 20, 281-292. doi: 10.1038/cdd.2012.124.
117. Mailand, N., Bekker-Jensen, S., Faustrup, H., Melander, F., Bartek, J., Lukas, C., et al. (2007). RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 131, 887-900. doi: 10.1016/j.cell.2007.09.040.
118. Malatesta, M., Peschiaroli, A., Memmi, E. M., Zhang, J., Antonov, A., Green, D. R., et al. (2013). The Cul4A-DDB1 E3 ubiquitin ligase complex represses p73 transcriptional activity. Oncogene 32, 4721-4726. doi: 10.1038/onc.2012.463.
119. Mallette, F. A., Mattiroli, F., Cui, G., Young, L. C., Hendzel, M. J., Mer, G., et al. (2012). RNF8-and RNF168-dependent degradation of KDM4A/JMJD2A triggers 53BP1 recruitment to DNA damage sites. EMBO J. 31, 1865-1878. doi: 10.1038/emboj.2012.47.
120. Marshansky, V., Wang, X., Bertrand, R., Luo, H., Duguid, W., Chinnadurai, G., et al. (2001). Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J. Immunol. 166, 3130-3142. doi: 10.4049/jimmunol.166.5.3130.
121. Meerang, M., Ritz, D., Paliwal, S., Garajova, Z., Bosshard, M., Mailand, N., et al. (2011). The ubiquitin-selective segregase VCP/p97 orchestrates the response to DNA double-strand breaks. Nat. Cell Biol. 13, 1376-1382. doi: 10.1038/ncb2367.
122. Meulmeester, E., Pereg, Y., Shiloh, Y., and Jochemsen, A. G. (2005). ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation. Cell Cycle 4, 1166-1170. doi: 10.4161/cc.4.9.1981.
123. Miyashita, T., and Reed, J. C. (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293-299. doi: 10.1016/0092-8674(95)90412-3.
124. Mizuno, K., Osada, H., Konishi, H., Tatematsu, Y., Yatabe, Y., Mitsudomi, T., et al. (2002). Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene 21, 2328-2333. doi: 10.1038/sj.onc.1205402.
125. Momand, J., Jung, D., Wilczynski, S., and Niland, J. (1998). The MDM2 gene amplification database. Nucleic Acids Res. 26, 3453-3459. doi: 10.1093/nar/26.15.3453.
126. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245. doi: 10.1016/0092-8674(92)90644-R.
127. Moynahan, M. E., and Jasin, M. (2010). Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat. Rev. Mol. Cell Biol. 11, 196-207. doi: 10.1038/nrm2851.
128. Nag, A., Bagchi, S., and Raychaudhuri, P. (2004). Cul4A physically associates with MDM2 and participates in the proteolysis of p53. Cancer Res. 64, 8152-8155. doi: 10.1158/0008-5472.CAN-04-2598.
129. Nakano, K., and Vousden, K. H. (2001). PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7, 683-694. doi: 10.1016/S1097-2765(01)00214-3.
130. Ni Chonghaile, T., and Letai, A. (2008). Mimicking the BH3 domain to kill cancer cells. Oncogene 27, S149-S157. doi: 10.1038/onc.2009.52.
131. Nijman, S. M., Luna-Vargas, M. P., Velds, A., Brummelkamp, T. R., Dirac, A. M., Sixma, T. K., et al. (2005). A genomic and functional inventory of deubiquitinating enzymes. Cell 123, 773-786. doi: 10.1016/j.cell.2005.11.007.
132. Nikrad, M., Johnson, T., Puthalalath, H., Coultas, L., Adams, J., and Kraft, A. S. (2005). The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol. Cancer Ther. 4, 443-449. doi: 10.1158/1535-7163.MCT-04-0260.
133. Norbury, C. J., and Zhivotovsky, B. (2004). DNA damage-induced apoptosis. Oncogene 23, 2797-2808. doi: 10.1038/sj.onc.1207532.
134. Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., et al. (2000). Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288, 1053-1058. doi: 10.1126/science.288.5468.1053.
135. Orlowski, R. Z., and Kuhn, D. J. (2008). Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin. Cancer Res. 14, 1649-1657. doi: 10.1158/1078-0432.CCR-07-2218.
136. Pan, M. R., Peng, G., Hung, W. C., and Lin, S. Y. (2011). Monoubiquitination of H2AX protein regulates DNA damage response signaling. J. Biol. Chem. 286, 28599-28607. doi: 10.1074/jbc. M111.256297.
137. Pan, Y., and Chen, J. (2003). MDM2 promotes ubiquitination and degradation of MDMX. Mol. Cell. Biol. 23, 5113-5121. doi: 10.1128/MCB.23.15.5113-5121.2003.
138. Parsons, J. L., Dianova, II, Khoronenkova, S. V., Edelmann, M. J., Kessler, B. M., and Dianov, G. L. (2011). USP47 is a deubiquitylating enzyme that regulates base excision repair by controlling steady-state levels of DNA polymerase beta. Mol. Cell 41, 609-615. doi: 10.1016/j.molcel.2011.02.016.
139. Parsons, J. L., Tait, P. S., Finch, D., Dianova, I. I., Edelmann, M. J., Khoronenkova, S. V., et al. (2009). Ubiquitin ligase ARF-BP1/Mule modulates base excision repair. EMBO J. 28, 3207-3215. doi: 10.1038/emboj.2009.243.
140. Peng, J., Schwartz, D., Elias, J. E., Thoreen, C. C., Cheng, D., Marsischky, G., et al. (2003). A proteomics approach to understanding protein ubiquitination. Nat. Biotechnol. 21, 921-926. doi: 10.1038/nbt849.
141. Pereg, Y., Shkedy, D., de Graaf, P., Meulmeester, E., Edelson-Averbukh, M., Salek, M., et al. (2005). Phosphorylation of Hdmx mediates its Hdm2-and ATM-dependent degradation in response to DNA damage. Proc. Natl. Acad. Sci. U.S.A. 102, 5056-5061. doi: 10.1073/pnas.0408595102.
142. Pickart, C. M. (2001). Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70, 503-533. doi: 10.1146/annurev.biochem.70.1.503.
143. Popovic, D., Vucic, D., and Dikic, I. (2014). Ubiquitination in disease pathogenesis and treatment. Nat. Med. 20, 1242-1253. doi: 10.1038/nm.3739.
144. Qi, C. F., Kim, Y. S., Xiang, S., Abdullaev, Z., Torrey, T. A., Janz, S., et al. (2012). Characterization of ARF-BP1/HUWE1 Interactions with CTCF, MYC, ARF and p53 in MYC-Driven B Cell Neoplasms. Int. J. Mol. Sci. 13, 6204-6219. doi: 10.3390/ijms13056204.
145. Qin, J. Z., Ziffra, J., Stennett, L., Bodner, B., Bonish, B. K., Chaturvedi, V., et al. (2005). Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 65, 6282-6293. doi: 10.1158/0008-5472.CAN-05-0676.
146. Ramadan, K., and Meerang, M. (2011). Degradation-linked ubiquitin signal and proteasome are integral components of DNA double strand break repair: new perspectives for anti-cancer therapy. FEBS Lett. 585, 2868-2875. doi: 10.1016/j.febslet.2011.04.046.
147. Ramesh, S., Qi, X. J., Wildey, G. M., Robinson, J., Molkentin, J., Letterio, J., et al. (2008). TGF beta-mediated BIM expression and apoptosis are regulated through SMAD3-dependent expression of the MAPK phosphatase MKP2. EMBO Rep. 9, 990-997. doi: 10.1038/embor.2008.158.
148. Rossi, M., Aqeilan, R. I., Neale, M., Candi, E., Salomoni, P., Knight, R. A., et al. (2006). The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc. Natl. Acad. Sci. U.S.A. 103, 12753-12758. doi: 10.1073/pnas.0603449103.
149. Rossi, M., De Laurenzi, V., Munarriz, E., Green, D. R., Liu, Y. C., Vousden, K. H., et al. (2005). The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J. 24, 836-848. doi: 10.1038/sj.emboj.7600444.
150. Sakai, M., Hibi, K., Kanazumi, N., Nomoto, S., Inoue, S., Takeda, S., et al. (2005). Aberrant methylation of the CHFR gene in advanced hepatocellular carcinoma. Hepatogastroenterology. 52, 1854-1857.
151. Santin, I., Moore, F., Grieco, F. A., Marchetti, P., Brancolini, C., and Eizirik, D. L. (2012). USP18 is a key regulator of the interferon-driven gene network modulating pancreatic beta cell inflammation and apoptosis. Cell Death Dis. 3, e419. doi: 10.1038/cddis.2012.158.
152. Sarek, G., and Ojala, P. M. (2007). p53 reactivation kills KSHV lymphomas efficiently in vitro and in vivo: new hope for treating aggressive viral lymphomas. Cell Cycle 6, 2205-2209. doi: 10.4161/cc.6.18.4730.
153. Satoh, A., Toyota, M., Itoh, F., Sasaki, Y., Suzuki, H., Ogi, K., et al. (2003). Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res. 63, 8606-8613.
154. Sawada, G., Ueo, H., Matsumura, T., Uchi, R., Ishibashi, M., Mima, K., et al. (2013). Loss of COP1 expression determines poor prognosisin patients with gastric cancer. Oncol. Rep. 30, 1971-1975. doi: 10.3892/or.2013.2664.
155. Scheffner, M., Huibregtse, J. M., Vierstra, R. D., and Howley, P. M. (1993). The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75, 495-505. doi: 10.1016/0092-8674(93)90384-3.
156. Scheffner, M., Nuber, U., and Huibregtse, J. M. (1995). Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 373, 81-83. doi: 10.1038/373081a0.
157. Schlesinger, D. H., Goldstein, G., and Niall, H. D. (1975). The complete amino acid sequence of ubiquitin, an adenylate cyclase stimulating polypeptide probably universal in living cells. Biochemistry 14, 2214-2218. doi: 10.1021/bi00681a026.
158. Schwickart, M., Huang, X., Lill, J. R., Liu, J., Ferrando, R., French, D. M., et al. (2010). Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 463, 103-107. doi: 10.1038/nature08646.
159. Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., et al. (2008). Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl. Acad. Sci. U.S.A. 105, 3933-3938. doi: 10.1073/pnas.0708917105.
160. Sheng, Y., Laister, R. C., Lemak, A., Wu, B., Tai, E., Duan, S., et al. (2008). Molecular basis of Pirh2-mediated p53 ubiquitylation. Nat. Struct. Mol. Biol. 15, 1334-1342. doi: 10.1038/nsmb.1521.
161. Sheng, Y., Saridakis, V., Sarkari, F., Duan, S., Wu, T., Arrowsmith, C. H., et al. (2006). Molecular recognition of p53 and MDM2 by USP7/HAUSP. Nat. Struct. Mol. Biol. 13, 285-291. doi: 10.1038/nsmb1067.
162. Shi, D., Pop, M. S., Kulikov, R., Love, I. M., Kung, A. L., and Grossman, S. R. (2009). CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proc. Natl. Acad. Sci. U.S.A. 106, 16275-16280. doi: 10.1073/pnas.0904305106.
163. Shibata, Y., Haruki, N., Kuwabara, Y., Ishiguro, H., Shinoda, N., Sato, A., et al. (2002). Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis 23, 1695-1699. doi: 10.1093/carcin/23.10.1695.
164. Shiloh, Y. (2003). ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 3, 155-168. doi: 10.1038/nrc1011.
165. Shiloh, Y., and Ziv, Y. (2013). The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat. Rev. Mol. Cell Biol. 14, 197-210. doi: 10.1038/nrm3546.
166. Shimada, M., Kitagawa, K., Dobashi, Y., Isobe, T., Hattori, T., Uchida, C., et al. (2009). High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers. Cancer Sci. 100, 866-872. doi: 10.1111/j.1349-7006.2009.01122.x.
167. Stevenson, L. F., Sparks, A., Allende-Vega, N., Xirodimas, D. P., Lane, D. P., and Saville, M. K. (2007). The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J. 26, 976-986. doi: 10.1038/sj.emboj.7601567.
168. Strasser, A., Harris, A. W., Jacks, T., and Cory, S. (1994). DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79, 329-339. doi: 10.1016/0092-8674(94)90201-1.
169. Sun, X. X., Challagundla, K. B., and Dai, M. S. (2012). Positive regulation of p53 stability and activity by the deubiquitinating enzyme Otubain 1. EMBO J. 31, 576-592. doi: 10.1038/emboj.2011.434.
170. Surget, S., Descamps, G., Brosseau, C., Normant, V., Maiga, S., Gomez-Bougie, P., et al. (2014). RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway. BMC Cancer 14:437. doi: 10.1186/1471-2407-14-437.
171. Tait, S. W., de Vries, E., Maas, C., Keller, A. M., D'Santos, C. S., and Borst, J. (2007). Apoptosis induction by Bid requires unconventional ubiquitination and degradation of its N-terminal fragment. J. Cell Biol. 179, 1453-1466. doi: 10.1083/jcb.200707063.
172. Tait, S. W., and Green, D. R. (2010). Mitochondria and cell death: outer membrane permeabilization and beyond. Nat. Rev. Mol. Cell Biol. 11, 621-632. doi: 10.1038/nrm2952.
173. Thirunavukarasou, A., Singh, P., Govindarajalu, G., Bandi, V., and Baluchamy, S. (2014). E3 ubiquitin ligase Cullin4B mediated polyubiquitination of p53 for its degradation. Mol. Cell. Biochem. 390, 93-100. doi: 10.1007/s11010-014-1960-3.
174. Thompson, S., Pearson, A. N., Ashley, M. D., Jessick, V., Murphy, B. M., Gafken, P., et al. (2011). Identification of a novel Bcl-2-interacting mediator of cell death (Bim) E3 ligase, tripartite motif-containing protein 2 (TRIM2), and its role in rapid ischemic tolerance-induced neuroprotection. J. Biol. Chem. 286, 19331-19339. doi: 10.1074/jbc. M110.197707.
175. Thrower, J. S., Hoffman, L., Rechsteiner, M., and Pickart, C. M. (2000). Recognition of the polyubiquitin proteolytic signal. EMBO J. 19, 94-102. doi: 10.1093/emboj/19.1.94.
176. Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., et al. (2006). Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl. Acad. Sci. U.S.A. 103, 1888-1893. doi: 10.1073/pnas.0507493103.
177. Toyota, M., Sasaki, Y., Satoh, A., Ogi, K., Kikuchi, T., Suzuki, H., et al. (2003). Epigenetic inactivation of CHFR in human tumors. Proc. Natl. Acad. Sci. U.S.A. 100, 7818-7823. doi: 10.1073/pnas.1337066100.
178. van de Kooij, B., Rooswinkel, R. W., Kok, F., Herrebout, M., de Vries, E., Paauwe, M., et al. (2013). Polyubiquitination and proteasomal turnover controls the anti-apoptotic activity of Bcl-B. Oncogene 32, 5439-5448. doi: 10.1038/onc.2013.99.
179. van Doorn, R., Zoutman, W. H., Dijkman, R., de Menezes, R. X., Commandeur, S., Mulder, A. A., et al. (2005). Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J. Clin. Oncol. 23, 3886-3896. doi: 10.1200/JCO.2005.11.353.
180. Vassilev, L. T. (2004). Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 3, 419-421. doi: 10.4161/cc.3.4.801.
181. Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., et al. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848. doi: 10.1126/science.1092472.
182. Voges, D., Zwickl, P., and Baumeister, W. (1999). The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 68, 1015-1068. doi: 10.1146/annurev.biochem.68.1.1015.
183. Wade, M., Li, Y. C., Matani, A. S., Braun, S. M., Milanesi, F., Rodewald, L. W., et al. (2012). Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells. Oncogene 31, 4789-4797. doi: 10.1038/onc.2011.625.
184. Wang, P., Wu, Y., Li, Y., Zheng, J., and Tang, J. (2013). A novel RING finger E3 ligase RNF186 regulate ER stress-mediated apoptosis through interaction with BNip1. Cell. Signal. 25, 2320-2333. doi: 10.1016/j.cellsig.2013.07.016.
185. Wang, X., Wang, J., and Jiang, X. (2011). MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J. Biol. Chem. 286, 23725-23734. doi: 10.1074/jbc. M110.213868.
186. Wang, X. M., Yang, L. Y., Guo, L., Fan, C., and Wu, F. (2009). p53-induced RING-H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection. Cancer 115, 4554-4563. doi: 10.1002/cncr.24494.
187. Wertz, I. E., Kusam, S., Lam, C., Okamoto, T., Sandoval, W., Anderson, D. J., et al. (2011). Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471, 110-114. doi: 10.1038/nature09779.
188. Wiggins, C. M., Johnson, M., and Cook, S. J. (2010). Refining the minimal sequence required for ERK1/2-dependent poly-ubiquitination and proteasome-dependent turnover of BIM. Cell. Signal. 22, 801-808. doi: 10.1016/j.cellsig.2010.01.004.
189. Wu, H., and Leng, R. P. (2011). UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation. Cell Cycle 10, 1912-1915. doi: 10.4161/cc.10.12.15882.
190. Wu, H., Pomeroy, S. L., Ferreira, M., Teider, N., Mariani, J., Nakayama, K. I., et al. (2011b). UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53. Nat. Med. 17, 347-355. doi: 10.1038/nm.2283.
191. Wu, H., Zeinab, R. A., Flores, E. R., and Leng, R. P. (2011c). Pirh2, a ubiquitin E3 ligase, inhibits p73 transcriptional activity by promoting its ubiquitination. Mol. Cancer Res. 9, 1780-1790. doi: 10.1158/1541-7786.MCR-11-0157.
192. Wu, J., Chen, Y., Lu, L. Y., Wu, Y., Paulsen, M. T., Ljungman, M., et al. (2011a). Chfr and RNF8 synergistically regulate ATM activation. Nat. Struct. Mol. Biol. 18, 761-768. doi: 10.1038/nsmb.2078.
193. Wu, X. R., Sha, J. J., Liu, D. M., Chen, Y. H., Yang, G. L., Zhang, J., et al. (2013). High expression of P53-induced Ring-h2 protein is associated with poor prognosis in clear cell renal cell carcinoma. Eur. J. Surg. Oncol. 39, 100-106. doi: 10.1016/j.ejso.2012.10.004.
194. Wu-Baer, F., Lagrazon, K., Yuan, W., and Baer, R. (2003). The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin. J. Biol. Chem. 278, 34743-34746. doi: 10.1074/jbc. C300249200.
195. Xia, M., Knezevic, D., Tovar, C., Huang, B., Heimbrook, D. C., and Vassilev, L. T. (2008). Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Cell Cycle 7, 1604-1612. doi: 10.4161/cc.7.11.5929.
196. Xiang, T., Li, L., Yin, X., Yuan, C., Tan, C., Su, X., et al. (2012). The ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 and is frequently silenced in breast cancer. PLoS ONE 7:e29783. doi: 10.1371/journal.pone.0029783.
197. Xie, D., Jauch, A., Miller, C. W., Bartram, C. R., and Koeffler, H. P. (2002). Discovery of over-expressed genes and genetic alterations in breast cancer cells using a combination of suppression subtractive hybridization, multiplex FISH and comparative genomic hybridization. Int. J. Oncol. 21, 499-507. doi: 10.3892/ijo.21.3.499.
198. Yamada, T., Christov, K., Shilkaitis, A., Bratescu, L., Green, A., Santini, S., et al. (2013a). p28, a first in class peptide inhibitor of cop1 binding to p53. Br. J. Cancer 108, 2495-2504. doi: 10.1038/bjc.2013.266.
199. Yamada, T., Das Gupta, T. K., and Beattie, C. W. (2013b). p28, an anionic cell-penetrating peptide, increases the activity of wild type and mutated p53 without altering its conformation. Mol. Pharm. 10, 3375-3383. doi: 10.1021/mp400221r.
200. Yuan, J., Luo, K., Zhang, L., Cheville, J. C., and Lou, Z. (2010). USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 140, 384-396. doi: 10.1016/j.cell.2009.12.032.
201. Yun, M. H., and Hiom, K. (2009). CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle. Nature 459, 460-463. doi: 10.1038/nature07955.
202. Zhang, H., Zhai, Y., Hu, Z., Wu, C., Qian, J., Jia, W., et al. (2010). Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat. Genet. 42, 755-758. doi: 10.1038/ng.638.
203. Zhang, S., Chea, J., Meng, X., Zhou, Y., Lee, E. Y., and Lee, M. Y. (2008). PCNA is ubiquitinated by RNF8. Cell Cycle 7, 3399-3404. doi: 10.4161/cc.7.21.6949.
204. Zhang, X., Berger, F. G., Yang, J., and Lu, X. (2011). USP4 inhibits p53 through deubiquitinating and stabilizing ARF-BP1. EMBO J. 30, 2177-2189. doi: 10.1038/emboj.2011.125.
205. Zhao, Y., Bernard, D., and Wang, S. (2013). Small molecule inhibitors of MDM2-p53 and MDMX-p53 interactions as new cancer therapeutics. Biodiscovery 8:4. doi: 10.7750/BioDiscovery.2013.8.4.
206. Zhong, Q., Gao, W., Du, F., and Wang, X. (2005). Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121, 1085-1095. doi: 10.1016/j.cell.2005.06.009.
207. Zhou, W., Zhu, P., Wang, J., Pascual, G., Ohgi, K. A., Lozach, J., et al. (2008). Histone H2A monoubiquitination represses transcription by inhibiting RNA polymerase II transcriptional elongation. Mol. Cell 29, 69-80. doi: 10.1016/j.molcel.2007.11.002.